Table 2 In vitro phenotypic activity of the library of spiro[pyrrolidine-3, 3´-oxindole] against MCF-7 and COS-7 cells.

From: Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification

Entry

Compound

Percentage inhibition a

EC50(μM) b

MCF-7

COS-7

MCF10A

MCF-7

1

5a

35.06 ± 0.09

11.73 ± 0.09

−

−

2

5b

33.10 ± 0.12

20.73 ± 0.11

−

−

3

5c

34.46 ± 0.11

28.80 ± 0.13

−

−

4

5d

44.25 ± 0.17

9.22 ± 0.12

−

−

5

5e

54.67 ± 0.08*

3.56 ± 0.19*

4.48

6.00*

6

5f

38.48 ± 0.18

34.87 ± 0.17

−

−

7

5g

25.29 ± 0.24

2.39 ± 0.23

−

−

8

5h

50.62 ± 0.24

25.20 ± 0.06

−

−

9

5i

53.66 ± 0.06*

15.60 ± 0.09*

0.8

4.01*

10

5j

38.72 ± 0.15

7.52 ± 0.15

−

−

11

5k

44.40 ± 0.09

7.14 ± 0.19

−

−

12

5l

60.96 ± 0.09*

15.42 ± 0.18*

0.08

3.53*

13

5m

31.81 ± 0.11

−0.51 ± 0.29

−

−

14

Etoposide

71.95 ± 0.11

77.65 ± 0.10

−

−

  1. aAll data is the mean of one experiment conducted in triplicates.
  2. bEC50 of 5e, 5i and 5l is the mean ± SD of three experiments.
  3. *Unless otherwise indicated, the differences were considered to be statistically significant at P < 0.05. The analyses were performed using GraphPad Prism Software version 5.02 (GraphPad Inc., La Jolla, CA, USA).
Back to article page